Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 5/2011

01.10.2011 | Case Report

A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy

verfasst von: Nawin Kumar, Prabhat Kumar Sinha, Krishna Pandey, Neena Verma, Chandra Shekhar Lal, Alok Ranjan, Rakesh Bihari Verma, Pradeep Das

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 5/2011

Einloggen, um Zugang zu erhalten

Abstract

Case We report a 32-year old relapse case of Visceral leishmaniasis, treated with Paromomycin who belonged from a endemic zone of Bihar state, India. After confirmation, he was treated with Amphotericin B, followed by Liposomal Amphotericin B in full course and even in higher dose. But after each therapy, the patient either did not responded or relapsed after treatment. Ultimately, the patient was successfully treated with combination therapy of Liposomal amphotericin B and Miltefosine without any relapse. Conclusion The multi-drug unresponsive Visceral leishmaniasis cases could pose a major threat to treatment strategy in the elimination program. In such situation, combination therapy seems to be a better approach that needs to be explored.
Literatur
1.
Zurück zum Zitat Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.PubMedCrossRef Badaro R, Jones TC, Carvalho EM, Sampaio D, Reed SG, Barral A, et al. New perspectives on a sub-clinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003–11.PubMedCrossRef
2.
Zurück zum Zitat Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104–7.CrossRef Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, et al. Failure of pentavalent antimony in visceral leishmaniasis in India. Clinical Infect Dis. 2000;31(4):1104–7.CrossRef
3.
Zurück zum Zitat Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536–8. Jha TK, Giri YN, Singh TK, Jha S. Use of amphotericin-B in drug- resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Hyg. 1995;52:536–8.
4.
Zurück zum Zitat Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571–81.CrossRef Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for Visceral Leishmaniasis in India. New England J Med. 2007;356(25):2571–81.CrossRef
5.
Zurück zum Zitat Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145–7.PubMedCrossRef Jochim RC, Teixeira C. Leishmania commandeers the host inflammatory response through neutrohils. Trends Parasitol. 2009;25(4):145–7.PubMedCrossRef
6.
Zurück zum Zitat Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59.PubMedCrossRef Alvar J, Aparicio P, Aseffa A, Boer MD, Cañavate C, Jean-Pierre Dedet, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev. 2008;21(2):334–59.PubMedCrossRef
7.
Zurück zum Zitat Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.PubMedCrossRef Lachaud L, Bourgeois N, Plourde M, Leprohon P, Bastien P, Ouellette M. Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum. Clin Infect Dis. 2009;48(2):e16–22.PubMedCrossRef
8.
Zurück zum Zitat Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229–35.PubMedCrossRef Seifert K, Perez-Victoria FJ, Stettler M, Sanchez-Canete MP, Castanys S, Gamarro F, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistant that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents. 2007;30(3):229–35.PubMedCrossRef
9.
Zurück zum Zitat Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2010;105(2):115–7.PubMedCrossRef Sundar S, Sinha PK, Verma DK, Kumar N, Alam S, Pandey K, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2010;105(2):115–7.PubMedCrossRef
10.
Zurück zum Zitat Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–86.PubMedCrossRef Sundar S, Sinha PK, Rai M, Verma DK, Kumar N, Alam S, et al. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet. 2011;377(9764):477–86.PubMedCrossRef
Metadaten
Titel
A rare case of Visceral leishmaniasis with multiple relapse and multi-drug unresponsive: successfully treated with combination therapy
verfasst von
Nawin Kumar
Prabhat Kumar Sinha
Krishna Pandey
Neena Verma
Chandra Shekhar Lal
Alok Ranjan
Rakesh Bihari Verma
Pradeep Das
Publikationsdatum
01.10.2011
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 5/2011
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-011-9544-8

Weitere Artikel der Ausgabe 5/2011

International Journal of Clinical Pharmacy 5/2011 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.